Loading
A phase 3 trial of Dexamethasone, Pamidronate, Thalidomide and Zoledronic acid in Multiple myeloma, run by National Cancer Institute (NCI), completed.
Dexamethasone With or Without Thalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma is a phase 3 interventional study registered as NCT00033332 by National Cancer Institute (NCI), started 2002-04 and reaching its primary completion in 2006-03. Interventions recorded: dexamethasone, pamidronate disodium, thalidomide, zoledronic acid. Conditions recorded: Multiple Myeloma and Plasma Cell Neoplasm.
Linked to the drug Pamidronate because the registry names it among its interventions and Multiple myeloma among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Pamidronate, Thalidomide, Zoledronic acid, Multiple myeloma and the tag pipeline.
Shares Pamidronate, Multiple myeloma and the tag pipeline.
Shares Zoledronic acid, Multiple myeloma and the tag pipeline.
Shares Dexamethasone, Multiple myeloma and the tag pipeline.
Shares Dexamethasone, Multiple myeloma and the tag pipeline.
Shares Zoledronic acid and the tag pipeline.
Shares Dexamethasone, Multiple myeloma and the tag pipeline.
Shares Dexamethasone, Multiple myeloma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/